

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl,
N-6MeNic-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-3-CNPhe-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
N-Ac-Sar-Gly-D-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl, and
N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.

31 (new). A composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 in an amount effective to inhibit angiogenesis.

32 (new). A composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 in an amount effective to inhibit growth of tumor cells.

REMARKS & ARGUMENTS

Claims 25, 27, and 30 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to make and or use the invention. Specifically, the Examiner maintains that the Applicants have not enabled that the claimed compounds inhibit angiogenesis *in vivo* or that the compounds inhibit tumor growth *in vivo*. Applicants traverse the rejections and respectfully request withdrawal of the same.

The Examiner has suggested that Applicants remove the term “pharmaceutical” from the claim 25. In order to expedite allowance, Applicants have amended claim 25 to remove the term.

The Examiner maintains that the term “therapeutically acceptable” in claim 30 is unclear. In order to expedite allowance, Applicants have amended claim 30 to remove the term.

The Examiner has suggested that Applicants cancel claim 27 for lack of enablement. Applicants have shown, however, that representative compounds described in Examples 1 to 109 inhibited human endothelial cell migration. Angiogenesis is the fundamental process by which new blood vessels are formed. As described in the

application, many diseases are driven by persistent unregulated angiogenesis. For example, ocular neovascularization has been implicated as the most common cause of blindness. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman, J., *Cancer Research*, 46: 467-473 (1986), Folkman, J., *Journal of the National Cancer Institute*, 82: 4-6 (1989)). Therefore, since Applicants have demonstrated the ability of the invented compounds to inhibit cell migration, thereby preventing angiogenesis, and since the diseases recited in claim 27 are known to be "angiogenic diseases" Applicants maintain that claim 27 is enabled. None-the-less, in order to expedite prosecution and allowance, Applicants cancel claim 36.


Applicants have added new claims 31 and 32 as the Examiner suggested.

ACTION REQUESTED

Allowance of claims 1-25 and 30-32 is respectfully requested. If the Examiner has any concerns he is invite to contact me directly at telephone number below.

Respectfully submitted,
Haviv, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623



Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants